Compare CASS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | CSTL |
|---|---|---|
| Founded | 1906 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.9M | 722.8M |
| IPO Year | 1996 | 2019 |
| Metric | CASS | CSTL |
|---|---|---|
| Price | $52.41 | $32.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $61.00 | $48.20 |
| AVG Volume (30 Days) | 54.7K | ★ 379.1K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ 87.77 | N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | $190,750,000.00 | ★ $344,229,000.00 |
| Revenue This Year | N/A | $13.96 |
| Revenue Next Year | $9.07 | $10.65 |
| P/E Ratio | $23.15 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $39.85 | $17.72 |
| 52 Week High | $59.63 | $44.28 |
| Indicator | CASS | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 44.07 |
| Support Level | $51.96 | $31.64 |
| Resistance Level | $52.82 | $34.23 |
| Average True Range (ATR) | 1.22 | 1.76 |
| MACD | -0.23 | -0.22 |
| Stochastic Oscillator | 6.58 | 19.48 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.